Promega, ATCC Partner on Bioassays for Biologics Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Promega and ATCC today announced a collaboration for cell banking and bioproduction of cells in order to create bioluminescence-based drug discovery assays for biologics.

The deal calls for ATCC to produce and authenticate cell banks and production lots of engineered and stock cell lines for use as cellular reagents as Promega creates a line of new cell-based assay systems for biologics. The initial system will be for biologics drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.